Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimising Melanoma Diagnostic Accuracy in Specialised Pigmented Lesion Clinics: A Five-Year Audit of Number Needed to Treat.

The Australasian journal of dermatology·2026
Same author

IGLON5: The diagnosis not to be missed.

Revue neurologique·2026
Same author

Glucose-6-phosphate dehydrogenase deficiency detection using fluorocytometric assay: Evaluation after 1 year of clinical implementation.

Cytometry. Part B, Clinical cytometry·2024
Same author

Plant growth promoting activities of endophytic bacteria from <i>Melia azedarach</i> (Meliaceae) and their influence on plant growth under gnotobiotic conditions.

Heliyon·2024
Same author

Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms.

ESMO open·2024
Same author

[Systematic analysis of evaluations of Objective Structured Clinical Exam (OSCE) multiple circuits: Explanatory variables and inter-rater correlations].

La Revue de medecine interne·2024

Related Experiment Video

Updated: May 26, 2025

Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions
10:08

Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions

Published on: February 24, 2021

5.8K

The COVID-19 pandemic reduced delays in the care pathway for patients with glioma at a French institute.

M Brison1, W Bouleftour2, J-B Pelletier3

  • 1University Hospital of Saint-Étienne, North Hospital, Department of Neurology, avenue Albert-Raimond, 42055 Saint-Étienne cedex, France.

Revue Neurologique
|February 23, 2025
PubMed
Summary

The COVID-19 pandemic accelerated glioma treatment pathways in French neuro-oncology patients. Despite initial delays, subsequent care stages improved, leading to faster treatment initiation for glioma patients.

Keywords:
COVID-19Care pathwayGliomaNeurooncologyNeurosurgery

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.8K
A 3D Spheroid Model for Glioblastoma
07:40

A 3D Spheroid Model for Glioblastoma

Published on: April 9, 2020

14.8K

Related Experiment Videos

Last Updated: May 26, 2025

Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions
10:08

Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions

Published on: February 24, 2021

5.8K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.8K
A 3D Spheroid Model for Glioblastoma
07:40

A 3D Spheroid Model for Glioblastoma

Published on: April 9, 2020

14.8K

Area of Science:

  • Neuro-oncology
  • Cancer Management
  • Epidemiology

Background:

  • The COVID-19 pandemic caused significant disruptions in cancer care.
  • Neuro-oncology patients face rapid disease progression, making timely management critical.
  • Limited data exists on the pandemic's impact on neuro-oncology patient care pathways.

Purpose of the Study:

  • To evaluate the effect of the COVID-19 pandemic on the therapeutic care of glioma patients at a French institute.
  • To analyze changes in treatment timelines during the pandemic period.

Main Methods:

  • Retrospective descriptive study utilizing electronic medical records.
  • Inclusion of all patients undergoing glioma surgery between January 2019 and December 2020.
  • Comparison of care pathway timelines before and during the pandemic.

Main Results:

  • 114 patients operated for glioma (70 in 2019, 44 in 2020).
  • 89% high-grade glioma, 81% glioblastoma.
  • Increased time from symptom onset to imaging (35 to 40 days).
  • Reduced time for surgery to histomolecular diagnosis (2 days) and diagnosis to results consultation (3 days).
  • Average treatment initiation post-surgery reduced from 49 days (2019) to 36 days (2020).

Conclusions:

  • The COVID-19 pandemic positively impacted the therapeutic care pathway for glioma patients.
  • Despite initial delays, overall care acceleration was observed.
  • The observed improvement in treatment timelines is crucial for this patient population.